Publications by authors named "Jason Stavropoulos"

Claim this Profile
M
Multimodal assessment of nervous and immune system responses following sciatic nerve injury.
Loren Lasko, Xin Huang, Martin J Voorbach, La Geisha R Lewis, Jason Stavropoulos

Pain· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Yunsong Tong, Jennifer J Bouska, Paul A Ellis, Eric F Johnson, Joel Leverson, Jason Stavropoulos

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Joann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, Jennifer J Bouska, Gail Bukofzer, Jason A Stavropoulos

Anticancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor.
Jieyi Wang, Lora A Tucker, Jason Stavropoulos, Qian Zhang, Yi-Chun Wang

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Cherrie K Donawho, Yan Luo, Yanping Luo, Thomas D Penning, Joy L Bauch, Jason A Stavropoulos

Clin Cancer Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
Alex R Shoemaker, Anatol Oleksijew, Joy Bauch, Barbara A Belli, Tony Borre, Jason Stavropoulos

Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Daniel H Albert, Paul Tapang, Terrance J Magoc, Lori J Pease, David R Reuter, Jason A Stavropoulos

Mol Cancer Ther· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis